A poor performance, due to cognitive impairments, on the Rookwood Driving Battery (RDB) — a set of tests aiming to evaluate specific neuropsychological skills that are important for safe vehicle operation — is the best predictor of poor driving among patients with Parkinson’s disease, a study has found.
The Parkinson’s Personal KinetiGraph (PKG), a small motion sensor device that can be worn on the wrist like a watch in patients with Parkinson’s disease, can be used to detect abnormal movements, especially those associated with bradykinesia at the earlier stages of the disorder, an observational…
Eisai is partnering with Wren Therapeutics to advance the discovery of new small molecule compounds capable of reducing the misfolding and aggregation of alpha-synuclein, the underlying cause of different neurological disorders, including Parkinson’s disease and dementia with Lewy bodies. The research collaboration will leverage Wren’s…
Two nonprofits, Parkinson’s U.K. and The Michael J. Fox Foundation have partnered with Neurolixis to support a clinical trial testing the safety, tolerability, and early efficacy of NLX-112, the company’s candidate to ease  dyskinesia and the severity of some non-motor symptoms due to Parkinson’s disease. Data from…
Levodopa, and especially levodopa/carbidopa intestinal gel (LCIG) — a formulation of levodopa and carbidopa infused directly into the intestines — can alter gut bacteria composition and metabolism, acting as drivers of bowel inflammation and possibly of disease progression in people with Parkinson’s disease, a study reported.
The U.S. Patent and Trademark Office (USPTO) has issued a patent covering the intellectual rights to Alterity Therapeutics’ next-generation compounds to treat several neurodegenerative disorders, including Parkinson’s disease. “This broad patent establishes an excellent foundation for the company to pursue multiple therapeutics across a…
Anavex 2-73 (blarcamesine) safely led to significant improvements in several aspects of cognition, including choice reaction time and episodic memory, in people with Parkinson’s disease dementia (PDD), new data from a Phase 2 trial report. According to Anavex Life Sciences, the therapy’s developer, these findings from…
Dopamine and serotonin — two brain chemicals involved in reward processing and whose pathways are treatment targets for diseases such as Parkinson’s — also play a key role in controlling the way people perceive the world and make decisions based on those perceptions, a study reported. According to its…
Certain types of anti-diabetic medications may lower the risk of Parkinson’s disease in people with type 2 diabetes, a population-based study suggests. In particular, the risk of Parkinson’s was found to be 36–60% lower in diabetic patients who were being treated with GLP-1 agonists or DPP4…
Simvastatin, a widely-used cholesterol-lowering medication, failed to slow the progression of Parkinson’s disease, according to data from a Phase 2 trial. Based on these findings, it was decided that a future Phase 3 study assessing the safety and efficacy of simvastatin in these patients would not be…
Get regular updates to your inbox.